Comparative Pharmacology
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDERGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDERGINE.
ERGOLOID MESYLATES vs HYDERGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
1-2 mg orally three times daily.
None Documented
None Documented
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Category A/B
Category C
Ergot Alkaloid
Ergot Alkaloid